Ronald E.  Blaylock net worth and biography

Ronald Blaylock Biography and Net Worth

Director of Pfizer
Founder, Managing Partner of Gennx360 Capital Partners, a private equity firm focused on investing in industrial and business services companies in the U.S. middle market, since 2006. Prior to launching Gennx360 Capital Partners, Mr. Blaylock founded and managed Blaylock & Company, an investment banking firm. Also held senior management positions at UBS, PaineWebber Group and Citicorp. Director of Advantage Solutions Inc., CarMax, Inc., and W.R. Berkley, Inc., an insurance holding company. Director of Urban One, Inc. from 2002 to 2019. Director of Syncreon U.S., a for-profit private company. Member of the Board of Trustees of Carnegie Hall. Member of the Board of Overseers of New York University Stern School of Business. Pfizer Director since 2017. Member of our Compensation and Audit Committees.

What is Ronald E. Blaylock's net worth?

The estimated net worth of Ronald E. Blaylock is at least $101,040.00 as of August 6th, 2020. Mr. Blaylock owns 4,000 shares of Pfizer stock worth more than $101,040 as of April 26th. This net worth estimate does not reflect any other assets that Mr. Blaylock may own. Learn More about Ronald E. Blaylock's net worth.

How do I contact Ronald E. Blaylock?

The corporate mailing address for Mr. Blaylock and other Pfizer executives is 235 EAST 42ND STREET, NEW YORK NY, 10017. Pfizer can also be reached via phone at (212) 733-2323. Learn More on Ronald E. Blaylock's contact information.

Has Ronald E. Blaylock been buying or selling shares of Pfizer?

Ronald E. Blaylock has not been actively trading shares of Pfizer within the last three months. Most recently, on Thursday, August 6th, Ronald E. Blaylock bought 13,000 shares of Pfizer stock. The stock was acquired at an average cost of $38.55 per share, with a total value of $501,150.00. Following the completion of the transaction, the director now directly owns 4,000 shares of the company's stock, valued at $154,200. Learn More on Ronald E. Blaylock's trading history.

Who are Pfizer's active insiders?

Pfizer's insider roster includes Ronald Blaylock (Director), Albert Bourla (DVM), Loretta Cangialosi (VP), William Carapezzi, Jr. (EVP), Albert D.V.M. (DVM), Frank Damelio (EVP), Frank D'Amelio (CFO & Exec. VP ), Jennifer Damico (SVP), Jennifer Damico (SVP), Scott Gottlieb (Director), Rady Johnson (Insider), Douglas Lankler (EVP), Alexander Mackenzie (EVP), Laurie Olson (Insider), Ian Read (CEO), Dawn Rogers (EVP), Sally Susman (Insider), and John Young (Insider). Learn More on Pfizer's active insiders.

Are insiders buying or selling shares of Pfizer?

In the last year, Pfizer insiders bought shares 3 times. They purchased a total of 5,000 shares worth more than $156,410.00. The most recent insider tranaction occured on December, 15th when Director Scott Gottlieb bought 3,000 shares worth more than $79,410.00. Insiders at Pfizer own 0.1% of the company. Learn More about insider trades at Pfizer.

Information on this page was last updated on 12/15/2023.

Ronald E. Blaylock Insider Trading History at Pfizer

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/6/2020Buy13,000$38.55$501,150.004,000View SEC Filing Icon  
See Full Table

Ronald E. Blaylock Buying and Selling Activity at Pfizer

This chart shows Ronald E Blaylock's buying and selling at Pfizer by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Pfizer Company Overview

Pfizer logo
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Read More

Today's Range

Now: $25.26
Low: $25.25
High: $26.43

50 Day Range

MA: $27.01
Low: $25.26
High: $28.37

2 Week Range

Now: $25.26
Low: $25.23
High: $40.37

Volume

47,041,425 shs

Average Volume

41,958,969 shs

Market Capitalization

$143.04 billion

P/E Ratio

70.17

Dividend Yield

6.38%

Beta

0.61